About Inbiopro
Inbiopro is a company based in Bengaluru (India) founded in 2007 was acquired by Strides Arcolab in December 2010. Inbiopro has raised $31.7 million across 6 funding rounds from investors including Accel, Strides Arcolab and Tenshi Life Sciences. The company has 1,124 employees as of October 31, 2024.
- Headquarter Bengaluru, India
- Employees 1124 as on 31 Oct, 2024
- Stage Minicorn
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Stelis Biopharma Private Limited
- Date of Incorporation 16 May, 2012
- Jurisdiction Bangalore, Karnataka, India
-
Annual Revenue
$3.02 M (USD)875as on Mar 31, 2021
-
Net Profit
-$16.28 M (USD)14as on Mar 31, 2021
-
EBITDA
-$9.48 M (USD)15as on Mar 31, 2021
-
Total Equity Funding
$31.7 M (USD)
in 6 rounds
-
Latest Funding Round
$11.26 M (USD), Series A
May 26, 2017
-
Investors
Accel
& 9 more
-
Employee Count
1124
as on Oct 31, 2024
-
Acquired by
Strides Arcolab
(Dec 09, 2010)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Inbiopro
Inbiopro has successfully raised a total of $31.7M across 6 strategic funding rounds. The most recent funding activity was a Series A round of $11.26 million completed in May 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Inbiopro
Inbiopro has secured backing from 10 investors, including institutional, angel, and venture fund investors. Prominent investors backing the company include Accel, Strides Arcolab and Tenshi Life Sciences.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Accel is recognized as a leading venture capital firm.
|
Locked | Locked | Locked | |
|
Delivers advanced finished dosage pharmaceuticals using global infrastructure and quality systems.
|
Locked | Locked | Locked | |
|
Manufacturer of IP-led niche finished dosage formulations and soft gelatin capsules
|
Locked | Locked | Locked |
Investor details for Inbiopro
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Inbiopro
Investment portfolio details for Inbiopro
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Inbiopro
Detailed financials for Inbiopro
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Inbiopro Comparisons
Peer comparison for Inbiopro
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Inbiopro
Detailed competitors of Inbiopro
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Inbiopro
Complete news archive for Inbiopro
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Inbiopro
Inbiopro was founded in 2007.
Inbiopro is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
Inbiopro is a funded company, having raised a total of $31.7M across 6 funding rounds to date.
As of Oct 31, 2024, the latest employee count at Inbiopro is 1,124.
Annual revenue of Inbiopro is $3.02M as on Mar 31, 2021.
Inbiopro Solutions, a biopharmaceutical company, develops and manufactures biologicals in India. It offers biosimilars; and therapeutics in the areas of oncology, rheumatoid arthritis, cardio vascular diseases, and others. The company also provides molecular biology outsourcing solutions, including de novo gene synthesis, gene cloning, DNA construct, plasmid preparation, and site directed mutagenesis. In addition, it provides tools for the creation and characterization of stable cell lines expressing a gene of interest; transient transfection; assay development and screening; analytical servicesprotein characterization; and purity analysis services. Its biologics are made accessible through a network of licensing partnerships.
Inbiopro has 10 investors. Key investors include Accel, Strides Arcolab, Tenshi Life Sciences, gmspharmaceuticals, and B K Iyer.
The valuation of Inbiopro is $57.1M as of May 2017.